Allogene Therapeutics, Inc.
ALLO
$2.20
-$0.02-0.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 35.25% | 37.55% | 23.23% | 8.10% | 30.12% |
| Total Depreciation and Amortization | -5.44% | -3.43% | -14.76% | -12.83% | -7.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.30% | -64.97% | -36.94% | 7.17% | -56.22% |
| Change in Net Operating Assets | -103.83% | 97.60% | 87.84% | -46.80% | 203.90% |
| Cash from Operations | 24.79% | 32.70% | 38.62% | 5.31% | 31.67% |
| Capital Expenditure | 100.00% | 43.36% | -- | -1,137.50% | -41.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -39.10% | 116.12% | -41.19% | -71.66% | -18.41% |
| Cash from Investing | -38.81% | 115.71% | -41.25% | -72.10% | -18.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 36.84% | 376.58% | -98.58% | 544.85% | 3,605.16% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 56.05% | -- | -- |
| Cash from Financing | 36.84% | 376.58% | -95.33% | 747.88% | 3,605.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -42.15% | 87.84% | -91.74% | -2.01% | 72.40% |